Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
DOI

10.1016/S0140-6736(14)60226-9

Type

Journal

Lancet

Publication Date

29/03/2014

Volume

383

Pages

1103 - 1104

Keywords

Cost-Benefit Analysis, Humans, Immunization Programs, Infant, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, United Kingdom